- Home
- ENLV vs IGC Comparison
ENLV vs IGC Comparison
Compare ENLV & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- IGC
- Stock Information
- Founded
- ENLV 2005
- IGC 2005
- Country
- ENLV Israel
- IGC United States
- Employees
- ENLV N/A
- IGC N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- IGC Health Care
- Exchange
- ENLV Nasdaq
- IGC Nasdaq
- Market Cap
- ENLV 23.7M
- IGC 20.2M
- IPO Year
- ENLV 1995
- IGC N/A
- Fundamental
- Price
- ENLV $1.09
- IGC $0.31
- Analyst Decision
- ENLV Strong Buy
- IGC Strong Buy
- Analyst Count
- ENLV 2
- IGC 2
- Target Price
- ENLV $10.00
- IGC $3.88
- AVG Volume (30 Days)
- ENLV 58.0K
- IGC 230.9K
- Earning Date
- ENLV 05-30-2025
- IGC 08-07-2025
- Dividend Yield
- ENLV N/A
- IGC N/A
- EPS Growth
- ENLV N/A
- IGC N/A
- EPS
- ENLV N/A
- IGC N/A
- Revenue
- ENLV N/A
- IGC $1,236,000.00
- Revenue This Year
- ENLV N/A
- IGC N/A
- Revenue Next Year
- ENLV N/A
- IGC $16.45
- P/E Ratio
- ENLV N/A
- IGC N/A
- Revenue Growth
- ENLV N/A
- IGC 1.65
- 52 Week Low
- ENLV $0.81
- IGC $0.25
- 52 Week High
- ENLV $1.76
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- ENLV 65.75
- IGC 49.31
- Support Level
- ENLV $0.90
- IGC $0.30
- Resistance Level
- ENLV $1.07
- IGC $0.32
- Average True Range (ATR)
- ENLV 0.06
- IGC 0.02
- MACD
- ENLV 0.02
- IGC -0.00
- Stochastic Oscillator
- ENLV 70.37
- IGC 20.00
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.